Short Stature: Pediatric Case Discussion & Key Learning Points
Model Case Presentation
Patient Demographics
Name: Master Arjun, Age: 10 years, Gender: Male, Informant: Mother (Reliable)
Chief Complaints
- Short height noticed since 4 years of age
- Not keeping up with peers in height – 6 years
- No pubertal development – noted by parents (expected at this age for comparison)
History Summary
Master Arjun was born at term by normal vaginal delivery, birth weight 3.0 kg (normal), and length was normal. He grew normally until age 4, after which his height fell progressively below his peers. He has no history of chronic illness, recurrent infections, diarrhea, or vomiting. Appetite is normal. He is doing well in school with no learning difficulties. No polyuria or polydipsia. No history of headaches or visual disturbance. No features of hypothyroidism (cold intolerance, constipation, skin changes). No history of prolonged steroid use. Father reports he himself was a "late bloomer" — short during school but achieved a final height of 165 cm after a growth spurt at age 16.
Father's height: 165 cm. Mother's height: 152 cm. No family history of consanguinity. No siblings with similar complaints.
Calculated Mid-Parental Height (boys): [(152 + 13) + 165] / 2 = 165 cm ± 8.5 cm (Target range: 156.5 – 173.5 cm)
Examination Summary
| Parameter | Finding | Significance |
|---|---|---|
| Height | 122 cm | Below 3rd percentile (expected ~138 cm for age) |
| Height Age | ~7 years | 3 years behind chronological age |
| Weight | 25 kg | Appropriate for height age |
| Weight-for-Height | Normal | Rules out nutritional/systemic cause |
| BMI | 16.8 kg/m² | Normal |
| Upper:Lower Segment Ratio | 1:1 (normal) | Proportionate short stature |
| Arm Span | 122 cm | Equals height — proportionate |
| Tanner Stage | Stage 1 (prepubertal) | Delayed puberty |
| Skin | Normal | No myxedema, no dry skin |
| Facies | Normal, no dysmorphism | No Turner/Noonan/Down features |
| Thyroid | Not enlarged | — |
| Genitalia | Normal size for age | No micropenis |
| Fundus / Vision | Normal | No papilledema |
Growth velocity (from records): ~4 cm/year (low-normal for a pre-pubertal child).
No dysmorphic features, no signs of systemic disease, no signs of hypothyroidism or hypercortisolism.
✅ Complete Diagnosis
Constitutional Delay of Growth and Puberty (CDGP) — a Normal Variant of Short Stature. (Supported by: positive family history of delayed puberty, bone age delay, normal weight-for-height, proportionate short stature, otherwise healthy child with projected adult height within mid-parental range.)
💡 Why CDGP and not GHD?
In GHD: height velocity is markedly reduced (<4 cm/yr), bone age delay is proportional to height age, child appears chubby (truncal adiposity), and there may be micropenis, midline defects, or history of perinatal insult. In this case, the family history of delayed puberty, normal weight-for-height, and projected height within MPH range strongly favour CDGP over pathological causes.
📝 History — Exam Q&A
Short stature is defined as a height more than 2 standard deviations (SD) below the mean for age, sex, and population — corresponding to below the 3rd percentile on a standard growth chart.
It can also be considered when:
- Height velocity is consistently below the 25th percentile over 6–12 months, OR
- Child is excessively short compared to the mid-parental height, even if absolute height is within normal range.
💡 Key Rule
A height <3 SD below mean (below ~0.1 percentile) is more likely to have a pathological cause (~80% of cases). Heights between −2 SD and −3 SD are more often normal variants (~80%).
| Age Group | Normal Growth Velocity |
|---|---|
| Infancy (0–1 year) | ~25 cm/year |
| 1–2 years | ~12–13 cm/year |
| 2–3 years | ~8–9 cm/year |
| 3 years to puberty | ~5–7 cm/year |
| Pubertal growth spurt | 8–14 cm/year (peak velocity) |
Minimum acceptable growth velocity (below which pathology must be excluded):
Age 2–4 yrs: <5.5 cm/yr; Age 4–6 yrs: <5 cm/yr; Age >6 yrs: <4 cm/yr
MPH (also called target height) estimates the child's genetic height potential based on parental heights.
| For Boys | For Girls |
|---|---|
| MPH = [(Mother's height + 13 cm) + Father's height] / 2 | MPH = [(Father's height – 13 cm) + Mother's height] / 2 |
| Target height range = MPH ± 8.5 cm (i.e., ±2 SD) | |
A child's projected adult height differing from MPH by more than 10 cm suggests a possible pathological cause.
I. Normal Variant (Physiological) — Most Common (~90%)
- Constitutional Delay of Growth and Puberty (CDGP) — "late bloomer"; bone age delayed, puberty delayed, normal final height.
- Familial (Genetic) Short Stature (FSS) — short parents, normal bone age, normal pubertal timing, final height is short but within MPH range.
- Idiopathic Short Stature (ISS) — short stature (<−2 SD), no identified cause, normal GH response.
II. Pathological Short Stature
- Endocrine causes: GH deficiency, hypothyroidism, Cushing syndrome, poorly controlled diabetes mellitus, precocious puberty (eventual short stature due to early epiphyseal fusion)
- Systemic/Chronic illness: Malnutrition, celiac disease, Crohn's disease, chronic renal failure, cyanotic CHD, chronic anemia (thalassemia), HIV
- Genetic/Chromosomal syndromes: Turner syndrome (45,X), Down syndrome, Noonan syndrome, Prader-Willi syndrome, Silver-Russell syndrome, SHOX haploinsufficiency
- Skeletal dysplasias: Achondroplasia, hypochondroplasia (disproportionate short stature)
- Intrauterine Growth Restriction (IUGR) / SGA — without catch-up growth
- Psychosocial dwarfism (Deprivation dwarfism) — reversible with improved environment
- Iatrogenic: Chronic corticosteroids, ADHD stimulants, anticonvulsants
| Feature | CDGP | Familial Short Stature (FSS) |
|---|---|---|
| Birth weight/length | Normal | May be small |
| Growth velocity | Normal (low-normal) | Normal |
| Bone age | Delayed (≥2 years behind) | Normal (= chronological age) |
| Pubertal timing | Delayed | Normal |
| Family history | Delayed puberty in parent | Short stature in parent(s) |
| Final adult height | Normal — within MPH range | Short — within MPH range but below 3rd percentile |
| Height SDS | Matches bone age SDS | Matches parental SDS |
💡 Mnemonic
CDGP: "The wait-and-see" — delayed but normal eventual height.
FSS: "The apple doesn't fall far from the tree" — short like parents but otherwise normal.
Antenatal & Birth History:
- Birth weight and length — SGA/IUGR suggests primordial/SGA short stature
- Perinatal hypoxia, hypoglycemia, prolonged jaundice — suggests GHD (perinatal insult to pituitary)
- Maternal illness, drugs, alcohol, smoking during pregnancy
Growth Pattern:
- When was short stature first noted? (Early vs late onset)
- Growth chart records — crossing percentiles? Rate of deceleration?
- Weight gain pattern — weight-for-height normal or low?
Systemic Review:
- Diarrhea, malabsorption — celiac, IBD, CF
- Polyuria/polydipsia — Diabetes insipidus (craniopharyngioma), DM
- Headache, vomiting, visual changes — intracranial tumour (craniopharyngioma)
- Cold intolerance, constipation, dry skin — hypothyroidism
- Easy bruising, striae, weight gain — Cushing syndrome
Drug History: Corticosteroids (inhaled/systemic), ADHD stimulants (methylphenidate), anticonvulsants
Family History:
- Heights of father, mother, siblings, grandparents
- Age of puberty in parents — CDGP runs in families
- Consanguinity, genetic disorders
Social History: Dietary intake, emotional deprivation (psychosocial dwarfism)
- Height <3 SD below mean (very severe short stature)
- Growth velocity consistently below normal for age
- Height more than 10 cm below MPH (disproportionately short for family)
- Normal birth weight → progressive slowing — suggests endocrine/systemic cause
- Associated systemic symptoms (diarrhea, polyuria, headache, visual changes)
- Perinatal insult: hypoxia, hypoglycemia, jaundice, midline defect (cleft palate)
- Chronic medication use: corticosteroids, stimulants
- Abnormal weight gain: overweight with short stature → hypothyroidism or Cushing; underweight → malnutrition or systemic illness
- Emotional deprivation or neglect history
Height age is the age at which the child's current height corresponds to the 50th percentile on a standard growth chart.
Use: Helps gauge the degree of growth retardation. For example, a 10-year-old child with a height of 122 cm has a height age of ~7 years — meaning the child is growing like a 7-year-old.
Weight age is similarly defined. In endocrinopathies (GHD, hypothyroidism), the weight age is more preserved relative to height age (child appears chubby for height).
- Birth length and weight are typically normal (GH is not the major driver of intrauterine growth)
- Growth slowing becomes apparent from 6–12 months of age onward
- Progressive decline in height SDS throughout the first 4–5 years — a distinguishing feature from CDGP and FSS
- Growth velocity is markedly reduced (<4 cm/yr in older children)
- Bone age delay equals or exceeds the height age delay
- Child appears "cherubic" — central/truncal adiposity, relatively immature facies with frontal bossing, midfacial hypoplasia, saddle nose
- In congenital GHD: micropenis in boys, hypoglycemia in neonates, prolonged jaundice
- Midline defects (cleft palate, septo-optic dysplasia) suggest associated panhypopituitarism
A reversible form of short stature caused by severe emotional deprivation, child abuse, or neglect. The mechanism involves stress-induced suppression of GH secretion — GH levels are paradoxically low despite no structural pituitary abnormality.
Key features:
- History of emotional abuse, neglect, institutionalization
- Low GH on testing — can mimic GHD
- Dramatic catch-up growth when removed from the depriving environment
- GH levels normalize in a nurturing environment — this test is diagnostic
🩺 Examination — Exam Q&A
- Under 2 years: Measure length in the supine position using an infantometer (length board). Two people required.
- Over 2 years: Measure standing height using a wall-mounted stadiometer. Child stands barefoot with heels, buttocks, shoulders, and occiput touching the wall (Frankfort plane — outer canthus and external auditory meatus at the same horizontal level).
- Measure at the same time each day (height decreases ~1–2 cm through the day due to spinal compression).
- Two measurements at least 6 months apart are needed to calculate growth velocity.
- Inaccurate measurement is the most common reason for unnecessary referral.
Distinguishes proportionate from disproportionate short stature.
| Assessment | Normal Values | Use |
|---|---|---|
| Upper:Lower segment ratio (U:L) | Newborn ~1.7:1 → By 8–10 yrs ~1:1 | Long legs relative to trunk = normal; short limbs = skeletal dysplasia |
| Arm span | = Height ± 5 cm | Arm span > height by >5 cm suggests SHOX mutation or Marfan; arm span much < height suggests short limbs |
| Sitting height | ~52% of total height | Elevated in short-limbed dwarfism |
💡 Key Distinction
Proportionate short stature → Most endocrine, nutritional, chromosomal causes (Turner, CDGP, GHD, hypothyroidism).
Disproportionate short stature → Skeletal dysplasias (achondroplasia = short limbs; spondyloepiphyseal dysplasia = short trunk).
- Cherubic facies: Frontal bossing, midfacial hypoplasia, saddle nose, small chin, immature-looking face
- Truncal (central) adiposity with relative muscle hypotonia
- Micropenis (in congenital GHD in males)
- Delayed dentition, small hands and feet
- High-pitched voice (due to small larynx)
- Skin: fine and thin (doll-like skin)
- No dysmorphic features
- Signs of associated hormone deficiencies (TSH deficiency → hypothyroid signs; ACTH deficiency → pallor, hypoglycemia risk)
- Midline defects: cleft palate, single central incisor → suggest panhypopituitarism
Turner syndrome (45,X) should be suspected in any girl with unexplained short stature — even with subtle or absent dysmorphism.
| System | Feature |
|---|---|
| Neck | Webbed neck (pterygium colli), low posterior hairline |
| Chest | Shield chest (broad with wide-spaced nipples), pectus excavatum |
| Limbs | Cubitus valgus (increased carrying angle), short 4th metacarpal |
| Hands/Feet | Lymphedema (especially in newborns), nail dysplasia |
| Eyes | Epicanthal folds, ptosis |
| Ears | Low-set, prominent |
| Heart | Bicuspid aortic valve, coarctation of aorta (check BP in all 4 limbs) |
| Puberty | Primary amenorrhoea, absent/incomplete puberty (ovarian dysgenesis) |
- Dull, placid face; puffy eyelids; macroglossia; coarse facies
- Dry, coarse skin; brittle hair; dry hair
- Cold peripheries; generalized edema (myxedema)
- Bradycardia
- Delayed relaxation of deep tendon reflexes (hung-up reflexes)
- Goitre (in Hashimoto thyroiditis / iodine deficiency)
- Disproportionate weight gain relative to height (obesity + short stature)
- Delayed dentition, delayed bone age (markedly out of proportion)
💡 Key Clue
In hypothyroidism: bone age delay is disproportionately greater than height age delay. Also, the child is typically overweight for height, unlike GHD where weight-for-height is normal to mildly elevated.
- Truncal obesity with moon face and buffalo hump
- Plethora (red, rounded face)
- Violaceous (purple) striae on abdomen, thighs, axillae
- Hypertension
- Hirsutism, acne
- Proximal muscle weakness
- Easy bruising, skin fragility
Key point: In Cushing syndrome, short stature occurs with obesity — the child gains weight but fails to grow in height. In exogenous obesity (simple obesity), children are often tall for age, not short.
Tanner staging is essential — delayed puberty points toward CDGP or pathological hypogonadism; precocious puberty can paradoxically cause eventual short stature.
| Stage | Boys | Girls |
|---|---|---|
| I (Prepubertal) | Testes <4 mL | No breast development |
| II | Testes 4–8 mL, scrotal thinning, pubic hair | Breast budding (thelarche), pubic hair |
| III | Testes 8–12 mL, penile lengthening | Further breast enlargement |
| IV | Testes 12–15 mL, adult-like pubic hair | Areola forms secondary mound |
| V | Adult size and configuration | Adult breast, menarche |
Normal onset of puberty: Boys — 9–14 years. Girls — 8–13 years. Delayed puberty = no puberty by age 14 in boys, 13 in girls.
Achondroplasia is the most common skeletal dysplasia, caused by a gain-of-function mutation in FGFR3 gene (autosomal dominant; 80% de novo mutations).
Clinical features (Disproportionate short stature — short limbs with normal trunk):
- Rhizomelic shortening (proximal > distal limbs)
- Large head with frontal bossing, midface hypoplasia
- Trident hands (widened space between 3rd and 4th fingers)
- Lumbar lordosis, genu varum
- Normal intelligence
- Foramen magnum stenosis (risk of cervicomedullary compression)
Average adult height: males ~131 cm, females ~124 cm.
🔬 Investigations — Exam Q&A
Bone age (skeletal age) reflects the degree of skeletal maturation — the actual maturity of bones compared to standard radiographic atlases, irrespective of chronological age.
Method: X-ray of the left hand and wrist — assessed using the Greulich and Pyle Atlas (most widely used) or the Tanner-Whitehouse (TW) method.
| Condition | Bone Age |
|---|---|
| CDGP | Delayed (≥2 years behind CA) but matches height age |
| Familial Short Stature | Normal (= chronological age) |
| GHD | Delayed (proportional to height delay) |
| Hypothyroidism | Markedly delayed (more than height delay) |
| Cushing syndrome | Delayed |
| Precocious puberty | Advanced (ahead of chronological age) |
| Turner syndrome | Normal or slightly delayed |
Basic screening (all children with short stature):
- Bone age (X-ray left hand and wrist)
- Complete Blood Count — chronic anaemia (thalassemia), infections
- Urine routine and microscopy — renal tubular acidosis, CKD
- Serum creatinine, BUN — chronic renal failure
- Serum electrolytes — renal tubular acidosis
- Liver function tests — chronic liver disease
- Thyroid function tests (TSH, Free T4) — hypothyroidism
- Anti-tissue transglutaminase (anti-tTG) IgA / anti-endomysial antibody — celiac disease
- ESR — chronic inflammatory conditions, IBD
- Karyotype — in all girls with unexplained short stature (rule out Turner syndrome)
💡 Remember
Celiac disease and growth hormone axis abnormalities are the two most commonly identified diseases in a systematic investigation of short stature.
Indications for GH evaluation:
- Height <−2 SD with markedly reduced growth velocity (<4 cm/yr)
- Clinical features of GHD (cherubic facies, truncal adiposity, micropenis)
- History of perinatal risk factors for GHD
- After excluding systemic and thyroid causes
Step 1 — Screening tests (IGF-1 and IGFBP-3):
- IGF-1 (Insulin-like Growth Factor-1) — low in GHD; reflects integrated GH secretion. Age and pubertal-stage adjusted.
- IGFBP-3 (IGF Binding Protein-3) — more stable, less affected by nutrition; low in GHD.
Step 2 — GH Stimulation Tests (GHST) / Provocative Tests:
Since GH is secreted in a pulsatile fashion, random GH levels are meaningless. Two stimulation tests using different agents must be performed:
| Agent | Mechanism | Notes |
|---|---|---|
| Insulin (ITT — Gold standard) | Hypoglycemia stimulates GH | Risk: hypoglycemia; requires close monitoring; contraindicated in epilepsy, cardiovascular disease |
| Clonidine | α2-agonist → GHRH stimulation | Safe, widely used; causes sedation, hypotension |
| Glucagon | Counter-regulatory hormone | Safe; used in young children |
| L-Dopa (Levodopa) | Dopaminergic stimulation | Causes nausea; commonly used |
| Arginine | Stimulates GH release | Often combined with GHRH |
Interpretation: Peak stimulated GH <10 ng/mL on two separate tests = GHD.
(Some centres use <7 ng/mL; cutoffs vary by assay — always sex-steroid prime pubertal-age children before testing.)
MRI of the hypothalamo-pituitary region is indicated when GHD is confirmed biochemically, or when a structural cause is suspected clinically.
Findings to look for:
- Absent/ectopic posterior pituitary bright spot — commonest MRI finding in GHD
- Pituitary hypoplasia — small anterior pituitary
- Thin or interrupted pituitary stalk (stalk interruption syndrome)
- Craniopharyngioma — suprasellar calcified mass; most common pituitary region tumour causing GHD in children
- Septo-optic dysplasia, arachnoid cysts
🚨 Key Point
Craniopharyngioma is the most common cause of acquired GHD in children. It presents with: headache, vomiting, visual field defects (bitemporal hemianopia), and multiple pituitary hormone deficiencies. MRI shows a suprasellar calcified lesion.
| Suspected Cause | Key Investigation |
|---|---|
| Hypothyroidism | TSH (↑ in primary), Free T4 (↓) |
| Turner Syndrome | Karyotype (45,X or mosaic 45,X/46,XX) |
| GH Deficiency | IGF-1, IGFBP-3, GH stimulation tests, MRI brain |
| Cushing Syndrome | 24-hr urinary free cortisol, midnight salivary cortisol, low-dose dexamethasone suppression test |
| Celiac Disease | Anti-tTG IgA, total IgA; confirmed by duodenal biopsy |
| Chronic Renal Failure | Creatinine, GFR, urine microscopy, renal USG |
| Rickets (nutritional) | Ca, P, ALP (↑), PTH, 25-OH Vitamin D (↓), X-ray wrists (cupping, fraying) |
| Achondroplasia / skeletal dysplasia | Skeletal survey X-rays, FGFR3 gene mutation |
| Prader-Willi Syndrome | DNA methylation study (chromosome 15q11-q13), FISH |
| SHOX deficiency | SHOX gene sequencing/FISH; features: Madelung deformity, mesomelic shortening |
💊 Management — Exam Q&A
- GH deficiency (classical/idiopathic GHD)
- Turner syndrome
- Chronic Renal Insufficiency (pre-transplant)
- Prader-Willi Syndrome
- SGA/IUGR without catch-up growth by age 2–4 years
- Idiopathic Short Stature (ISS) — FDA approved (not universally recommended; controversial)
- SHOX deficiency
- Noonan syndrome
⚠️ Contraindications
Active malignancy, closed epiphyses (growth plates fused), active proliferative or severe non-proliferative diabetic retinopathy, critical illness (acute trauma, major surgery, respiratory failure). Use with caution in Prader-Willi with obesity/sleep apnea.
- Route: Daily subcutaneous injection, given at bedtime (mimics physiological nocturnal GH pulse)
- Dose for GHD: 25–35 mcg/kg/day (0.025–0.035 mg/kg/day)
- Dose for Turner syndrome: Higher — 45–50 mcg/kg/day
- Dose for SGA/ISS: 35–47 mcg/kg/day
- Best response in first year of treatment (8–13 cm height gain); decreasing response thereafter
Monitoring parameters:
- Growth velocity every 6–12 months
- IGF-1 levels (target: 0 SDS for GHD, up to +2 SDS for others)
- Thyroid function (may unmask secondary hypothyroidism)
- Blood glucose (risk of insulin resistance)
- Bone age annually
- Fundoscopy (risk of benign intracranial hypertension)
- Benign intracranial hypertension (pseudotumour cerebri) — headache, vomiting, papilledema; reversible on stopping GH
- Slipped Capital Femoral Epiphysis (SCFE) — limp, hip/knee pain; GH increases growth at the vulnerable epiphysis
- Insulin resistance / impaired glucose tolerance
- Local injection site reactions (lipodystrophy)
- Fluid retention / oedema (usually transient)
- Progression of scoliosis
- Worsening of pre-existing intracranial tumours (not de novo cancer causation)
- Theoretical long-term cancer risk (under study — not yet established in paediatric patients)
Primary approach: Reassurance and observation. Most children with CDGP will achieve normal adult height without treatment. Parents and child should be counseled that this is a normal variant.
If significant psychosocial distress or very delayed puberty: A short course of sex steroid therapy may be used to "prime" pubertal onset:
- Boys: Testosterone enanthate 50–100 mg IM monthly for 3–6 months
- Girls: Low-dose ethinyl oestradiol orally for 3–6 months
This induces secondary sexual characteristics and may improve psychological well-being without significantly compromising final adult height if started appropriately.
GH therapy is generally NOT indicated in CDGP — final adult height is normal without it.
| Cause | Treatment |
|---|---|
| Hypothyroidism | Levothyroxine replacement — excellent catch-up growth if treated early |
| Cushing syndrome | Treat the cause (surgery for pituitary/adrenal adenoma; stop exogenous steroids gradually) |
| GHD | Recombinant GH (rGH) — daily subcutaneous injections |
| Turner syndrome | rGH + oestrogen replacement at pubertal age |
| Celiac disease | Strict gluten-free diet — catch-up growth occurs |
| CRF | rGH pre-transplant; optimise nutrition and control acidosis |
| Malnutrition | Nutritional rehabilitation; treat underlying cause |
| Familial Short Stature | Reassurance; rGH may give modest height gain but not universally recommended |
| Psychosocial dwarfism | Provide nurturing environment — dramatic spontaneous catch-up growth |
| Achondroplasia | Vosoritide (CNP analogue, FGFR3 antagonist) — FDA approved 2021; limb-lengthening surgery in selected cases |
Laron Syndrome (Growth Hormone Insensitivity/Resistance) is caused by a defect in the GH receptor gene → cells cannot respond to GH → IGF-1 production is severely deficient despite high circulating GH levels.
| Feature | GHD | Laron Syndrome (GH Resistance) |
|---|---|---|
| GH levels | Low (fails stimulation) | High |
| IGF-1 levels | Low | Very Low |
| IGF-1 generation test | IGF-1 rises after exogenous GH | IGF-1 does NOT rise (receptor defect) |
| Treatment | Recombinant GH | Recombinant IGF-1 (Mecasermin) |
- Height <−2 SD with abnormal growth velocity
- Height <−3 SD (below 0.1 percentile) — regardless of velocity
- Projected adult height >10 cm below MPH
- Clinical suspicion of endocrine cause: GHD, hypothyroidism, Cushing, Turner
- Abnormal screening investigations (low TSH, low IGF-1, abnormal karyotype)
- IUGR/SGA without catch-up growth by age 2–4 years
- All girls with unexplained short stature (rule out Turner)
- Dysmorphic features suggesting genetic syndrome
🔭 Recent Advances — Exam Q&A
Traditional rGH requires daily subcutaneous injections, which is burdensome and reduces adherence. Long-acting GH preparations have been developed that require only once-weekly dosing:
- Somapacitan (Sogroya) — albumin-binding rGH analogue; once-weekly; FDA approved 2021 for adults; approved for children (2022)
- Lonapegsomatropin (Skytrofa) — prodrug of GH; once-weekly; FDA approved 2021 for children aged ≥1 year with GHD
- Somatrogon (Ngenla) — fusion protein; once-weekly; approved in multiple countries including India
Advantage: Once-weekly injection improves adherence, reduces injection burden, and maintains similar efficacy and safety to daily GH.
Vosoritide (Voxzogo) is a C-type natriuretic peptide (CNP) analogue that acts as an FGFR3 inhibitor — counteracting the gain-of-function mutation responsible for achondroplasia.
Mechanism: CNP binds to NPR-B receptor on chondrocytes → increases cGMP → inhibits the overactive FGFR3 pathway → restores endochondral bone growth at the growth plate.
Indication: Achondroplasia in children with open epiphyses (aged ≥2 years). FDA approved 2021. Given as once-daily subcutaneous injection.
Benefit: Significantly increases annualized growth velocity compared to placebo; first disease-modifying therapy for achondroplasia.
TransCon GH (Lonapegsomatropin) is a pegylated GH prodrug linked to PEG via a methionine residue that is gradually cleaved in circulation to release fully active native GH.
This results in sustained release over a week with a once-weekly dosing schedule. It was FDA approved as Skytrofa in 2021 for children with GHD (≥1 year old) and provides non-inferior annual height velocity compared to daily GH with similar safety.
Traditional GH dosing is weight-based (mcg/kg/day). However, there is significant inter-individual variability in GH sensitivity. IGF-1 based dosing individualizes GH dose by targeting a specific serum IGF-1 SDS (typically 0 to +2 SDS):
- If growth response is poor and IGF-1 is low → dose can be increased
- If IGF-1 exceeds +2.5 SDS → dose should be reduced (safety concern)
This approach helps avoid under-treatment or over-treatment, reduces adverse effects related to supra-physiologic IGF-1, and is recommended in the 2016 Pediatric Endocrine Society guidelines.
Mecasermin (Increlex) is recombinant human IGF-1. It is indicated for severe Primary IGF-1 deficiency (PIGFD) — conditions where GH cannot stimulate IGF-1 production despite being present in adequate levels.
Indications:
- Laron syndrome (GH receptor defect)
- GH gene deletion with neutralizing GH antibodies after rGH therapy
- Severe GH signal transduction defects
Main adverse effect: Hypoglycemia (IGF-1 has insulin-like activity) — must be given with a meal or snack. Also risk of tonsillar/lymphoid hypertrophy, intracranial hypertension, and injection site reactions.
⚡ Key Points — Quick Revision
One-Liners for Exam
- Short stature definition: Height <2 SD below mean (<3rd percentile) for age and sex
- Most common cause: Normal variant — CDGP or Familial Short Stature (~90%)
- MPH (boys): [(Mother's ht + 13 cm) + Father's ht] / 2 ± 8.5 cm
- MPH (girls): [(Father's ht – 13 cm) + Mother's ht] / 2 ± 8.5 cm
- Bone age assessment: X-ray left hand + wrist → Greulich & Pyle Atlas
- CDGP: Delayed bone age, delayed puberty, normal final height; family history of delayed puberty
- FSS: Normal bone age, normal puberty, short final height; family history of short stature
- GHD on MRI: Absent posterior pituitary bright spot / ectopic neurohypophysis / stalk interruption
- Most common pituitary tumour causing GHD in children: Craniopharyngioma
- GH stimulation test: Peak GH <10 ng/mL on ≥2 tests = GHD; Gold standard stimulus = Insulin
- Laron syndrome: High GH + Low IGF-1 (GH receptor defect) → treat with Mecasermin (rIGF-1)
- Turner syndrome: Karyotype all girls with unexplained short stature; treat with rGH + oestrogen
- Short stature + obesity: Think hypothyroidism or Cushing (unlike simple obesity where children are TALL)
- Disproportionate short stature (short limbs): Achondroplasia (FGFR3 mutation)
- Achondroplasia treatment: Vosoritide (CNP analogue, FGFR3 inhibitor) — FDA approved 2021
- rGH dosing: Daily SC injection at bedtime; 25–35 mcg/kg/day for GHD
- Long-acting GH (once weekly): Somapacitan, Lonapegsomatropin (Skytrofa), Somatrogon (Ngenla)
- Side effects of rGH: Pseudotumour cerebri, SCFE, insulin resistance
- Psychosocial dwarfism: GH low → normalize with nurturing environment → dramatic catch-up growth
- Celiac disease: Anti-tTG IgA is screening test; catch-up growth on gluten-free diet
🚨 Examiner Favourites
- Differentiate CDGP vs FSS vs GHD (bone age + family history + weight-for-height)
- Why is random GH level useless? (Pulsatile secretion — must use stimulation tests)
- Why is a short girl always karyotyped? (Turner syndrome may present with short stature alone)
- Short stature + obesity → hypothyroidism; Short stature + low weight → systemic illness/malnutrition
- Indications for rGH: GHD, Turner, CRI, Prader-Willi, SGA, ISS (FDA approved), SHOX deficiency